

# **Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease**

## **Supplementary Appendix**

### **TABLE OF CONTENTS**

Table S1. Characteristics of cohort from Erlangen, Germany	Page 2
Figure S1.	Page 3
Figure S2.	Page 4
Figure S3.	Page 5
Supplementary Methods	
Anti-SARS-CoV-2 IgG antibody titers	Page 6
Immune cell phenotyping by high-dimensional spectral flow cytometry	Page 6
Table S2. Antibodies used for high-dimensional spectral flow cytometry	Page 7
Figure S3	Page 8


**Supplementary Table 1.** Characteristics of cohort from Erlangen, Germany.

<b>Characteristic</b>	<b>Controls (n = 182)</b>	<b>IMID No MTX<sup>+</sup> (n =11)</b>	<b>IMID Yes MTX<sup>+</sup> (n = 20)</b>	<b>p-value</b>
<b>Age- mean (range, SD)</b>	40.8 [21-65, 12.0]	45.0 [26-80, 15.5]	54.5 [24-87, 19.2]	0.008
<b>Female- n (%)</b>	104 (57.1)	7 (58.3)	15 (75.0)	0.290
<b>Race- n (%)</b>				
White	178 (97.8)	11 (100.0)	19 (95.0)	0.680
Black	0 (0.0)	0 (0.0)	0 (0.0)	
Asian	2 (1.1)	0 (0.0)	1 (5.0)	
Other	1 (0.6)	0 (0.0)	0 (0.0)	
<b>Hispanic ethnicity- n (%)</b>	1 (0.6)	0 (0.0)	0 (0.0)	0.918
<b>Long term medication use- n (%)</b>				
Methotrexate	--	0 (0.0)	20 (100.0)	1.00
Tumor necrosis factor inhibitors	--	11 (100.0)	0 (0.0)	1.00
<b>Methotrexate dose- mean (SD)</b>	--	--	14.7 (4.2)	
<b>COVID-19 infection prior to vaccination- n(%)</b>	0 (0.0)	0 (0.0)	0 (0.0)	1.00
<b>Days from 1<sup>st</sup> vaccine mean (range, SD)</b>	47.7 (11-78,12.1)	42.1 (23-74,18.0)	44.0 (13-78,16.7)	0.204
<b>Number receiving 2<sup>nd</sup> vaccination dose- n (%)</b>	179 (98.4)	9 (81.8)	18 (90.0)	0.044
<b>Adequate humoral immunogenicity<sup>#</sup>- n (%)</b>	179 (98.4)	10 (90.9)	10 (50.0)	<0.001
<b>OD anti-SARS-CoV-2 IgG</b>				
Median (range)	9.4 (1.2-14)	7.8 (2.3-11.3)	5.9 (0.95-13.5)	<0.001


<sup>+</sup>IMID denotes immune-mediated inflammatory disease, MTX methotrexate, OD optical density.

<sup>\*</sup>Giant cell arteritis and polymyalgia rheumatica.


<sup>#</sup>Adequate response defined as within 2 standard deviations (SD) of the mean OD450nm of controls (OD 450nm >5.7units).



**Supplementary Figure 1.** Percentage of patients achieving adequate response to COVID-19 vaccination from New York and Erlangen cohorts combined (n=290). Percentages and group comparisons using chi squared test of independence reflect proportion of those achieving an adequate response within each group.  
 \*\*\*indicated p value less than .001.



**Supplementary Figure 2.** Percentage of total patients achieving adequate response to COVID-19 vaccination by age. Percentages and group comparisons using chi squared test of independence reflect proportion of those achieving an adequate response within each group. \*\*\*indicated p value less than .001.



**Supplementary Figure 3.** Percentage of total patients achieving a stricter definition of adequate response to COVID-19 vaccination. For the New York City cohort, adequate response is defined as greater than 1000 units and for the Erlangen cohort, adequate response is defined as greater than 5.0 (OD450nm). Percentages and group comparisons using chi squared test of independence reflect proportion of those achieving an adequate response within each group. \*\*\*indicated p value less than .001.

## Supplementary Methods

### Anti-SARS-CoV-2 IgG antibody titers


Direct ELISA was used to quantify antibody titers in the New York cohort participants serum. Ninety-six well plates were coated with 1 µg/ml S1 protein (100 µl/well) diluted in PBS and were then incubated overnight at 4°C (Sino Biological Inc., 40591-V08H). Plates were washed four times with 250 µl of PBS containing 0.05% Tween 20 (PBS-T) and blocked with 200 µl PBS-T containing 4% non-fat milk and 5% whey, as blocking buffer at RT for 1 hour. Sera were heated at 56°C for 1 hour prior to use. Samples were diluted to a starting concentration of 1:50 (S1) were first added to the plates and then serially diluted 1:3 in blocking solution. The final volume in all wells after dilution was 100 µl. After a 2-hour incubation period at RT, plates were washed four times with PBS-T. Horseradish-peroxidase conjugated goat-anti human IgG (Southern BioTech, 2040-05) were diluted in blocking buffer (1:2000) and 100 µl was added to each well. Plates were incubated for 1 hour at RT and washed four times with PBS-T. After developing for 5 min with TMB Peroxidase Substrate 3,3',5,5'-Tetramethylbenzidine (Thermo Scientific), the reaction was stopped with 1M sulfuric acid or 1N hydrochloric acid. The optical density was determined by measuring the absorbance at 450 nm on a Synergy 4 (BioTek) plate reader. In order to summarize data collected on individuals, the area under the response curve was calculated for each participant and end point titers were normalized using replicates of pooled positive control sera on each plate to reduce variability between plates. IgG antibodies against the S1 domain of the spike protein of SARS-CoV-2 were tested in the Erlangen participants using the commercial enzyme-linked immunosorbent assay from Euroimmun (Lübeck, Germany) on the EUROIMMUN Analyzer I platform and according to the manufacturers protocol. Optical density was determined at 450 nm with reference wavelength at 630 nm.

### Immune cell phenotyping by high-dimensional spectral flow cytometry

Peripheral blood was collected in sodium heparin collection tubes and PBMC were isolated using the SepMate system in accordance with manufacturer's instructions. PBMC were cryopreserved in fetal calf serum supplemented with 10% DMSO. Cryopreserved cells were thawed in batches for immunophenotyping studies. Then, 2 to 5 million freshly isolated PBMC were resuspended in HBSS supplemented with 1% fetal calf serum (Fisher) and 0.02% sodium azide (Sigma). Cells underwent Fc-blockade with Human TruStain FcX (Biolegend) and NovaBlock (Phitonex) for 10 minutes at room temperature, followed by surface staining antibody cocktail at room temperature for 20 minutes in the dark. Cells were permeabilized with the eBioscience Intracellular Fixation and Permeabilization kit (Fisher) for 20 minutes at room temperature in the dark, followed by intracellular staining with an antibody cocktail for 1 hour at room temperature in the dark. All samples were then resuspended in 1% paraformaldehyde and acquired within three days of staining on a 5-laser Aurora cytometer (Cytek Biosciences). Antibodies, clones, and catalog numbers are available in Table S3. Initial data quality control was performed using FlowJo.

**Supplementary Table 2. Antibodies used for high-dimensional spectral flow cytometry**

<b>Target</b>	<b>Fluorochrome</b>	<b>Clone</b>	<b>Manufacturer</b>	<b>Catalog #</b>
<b>Live/Dead Blue</b>	-	-	Invitrogen	L23105
<b>CD3</b>	APC/Fire 810	SK7	Biologend	344857
<b>CD4</b>	SparkBlue 550	SK3	Biologend	344656
<b>CD8</b>	PE-Fire 640	SK1	Biologend	344761
<b>CD11c</b>	PerCP	Bu15	Biologend	337234
<b>CD14</b>	BUV805	M5E2	BD	612902
<b>CD16</b>	BV480	3G8	BD	566171
<b>CD19</b>	BUV496	SJ25C1	BD	612939
<b>CD20</b>	APC	2H7	Biologend	302309
<b>CD21</b>	PE-Cy5	B-ly4	BD	551064
<b>CD23</b>	BUV615	M-L233	BD	751104
<b>CD25</b>	BUV563	2A3	BD	612919
<b>CD27</b>	SB702	O323	Invitrogen	67-0279-42
<b>CD38</b>	Qdot655	HIT2	Invitrogen	Q22150
<b>CD40</b>	BV510	5C3	Biologend	334330
<b>CD45RA</b>	Spark NIR 685	HI100	Biologend	304168
<b>CD56</b>	BV570	5.1H11	Biologend	362539
<b>CD71</b>	SB780	OKT9	Invitrogen	78-0719-42
<b>CD123</b>	BV650	7G3	BD	563405
<b>Recombinant Spike protein</b>	PE		Biologend	793804
<b>CD138</b>	PacBlue	MI15	Biologend	356531
<b>CD150 (CTLA4)</b>	BV421	BNI3	Biologend	369606
<b>CD183 (CXCR3)</b>	BV750	1C6	BD	746895
<b>CD185 (CXCR5)</b>	BB515	RF8B2	BD	564624
<b>CD197 (CCR7)</b>	BV605	G043H7	Biologend	353224
<b>CD278 (ICOS)</b>	APC-Fire750	C398.4A	Biologend	313536
<b>CD279 (PD-1)</b>	BB700	EH12.1	BD	566460
<b>HLA-DR</b>	BUV661	G46-6	BD	612980
<b>IgD</b>	BUV737	IA6-2	BD	612798
<b>Foxp3</b>	PE-Cy5.5	PCH101	Invitrogen	35-4776-42
<b>Tbet</b>	PE-Cy7	4B10	Biologend	644823
<b>Eomes</b>	PE-eF610	WD1928	Invitrogen	61-4877-42
<b>GzmB</b>	A700	GB11	BD	561016
<b>Ki67</b>	BUV395	B56	BD	564071
<b>IgG</b>	PerCP-Vio700	IS11-3B2.2.3	Miltenyi	130-119-880



**Supplementary Figure 4.** Flow cytometry gating strategy. (Left panel) Gating strategy and example plots for the key immune populations. (Right panel) Plots showing baseline or at the 4-week time point for CD19 specific for Spike protein (top row) or for expression of Granzyme B in CD8 T cells